Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a sell rating to a hold rating in a research note published on Monday morning.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

Several other brokerages have also weighed in on AUPH. BidaskClub raised shares of Aurinia Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, January 5th. HC Wainwright reaffirmed a buy rating and set a $12.00 price objective (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research report on Monday, October 30th. Cantor Fitzgerald reaffirmed a buy rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Royal Bank of Canada started coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, February 8th. They set an outperform rating and a $9.00 price objective on the stock. Finally, Canaccord Genuity set a $11.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $10.59.

Aurinia Pharmaceuticals (NASDAQ AUPH) opened at $5.32 on Monday. Aurinia Pharmaceuticals has a 52-week low of $3.23 and a 52-week high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Aurinia Pharmaceuticals had a negative net margin of 18,089.02% and a negative return on equity of 25.56%. The firm’s revenue was up .0% compared to the same quarter last year. equities analysts expect that Aurinia Pharmaceuticals will post -1.08 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its holdings in Aurinia Pharmaceuticals by 36.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock valued at $5,411,000 after purchasing an additional 319,639 shares during the last quarter. Franklin Resources Inc. grew its holdings in Aurinia Pharmaceuticals by 33.2% during the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock valued at $7,540,000 after purchasing an additional 414,400 shares during the last quarter. Hudson Bay Capital Management LP grew its holdings in Aurinia Pharmaceuticals by 20.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $2,039,000 after purchasing an additional 75,000 shares during the last quarter. Spark Investment Management LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $153,000. Finally, BlackRock Inc. acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at approximately $3,261,000. Institutional investors own 27.96% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Aurinia Pharmaceuticals (AUPH) Upgraded to “Hold” by Zacks Investment Research” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2018/02/15/aurinia-pharmaceuticals-auph-upgraded-to-hold-by-zacks-investment-research.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.